AI for Drug Development and Portfolio Management – with Leaders from Intelligencia AI and Novartis
This interview analysis is sponsored by Intelligencia AI and was written, edited, and published in alignment with our Emerj sponsored content guidelines. Learn more about our thought leadership and content creation services on our Emerj Media Services page. Rising costs, long development cycles, and uncertain success rates continue to challenge pharmaceutical R&D efficiency. According to…